Neogenomics Inc
SWB:NG9
Neogenomics Inc
SWB:NG9
Price:
7.67
EUR
-0.31%
Market Cap:
€1.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Neogenomics Inc
SWB:NG9
|
US |
|
Trillion Energy International Inc
F:Z620
|
CA |
|
C
|
Continental AG
XHAM:CON
|
DE |
|
MDA Ltd
TSX:MDA
|
CA |
|
A
|
ACI Worldwide Inc
F:TSA
|
US |
|
Origin Energy Ltd
ASX:ORG
|
AU |
|
S
|
SEGRO PLC
F:S4VC
|
UK |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
US |
|
V
|
Vishal Mega Mart Ltd
NSE:VMM
|
IN |
|
F
|
ForFarmers NV
SWB:5FF
|
NL |
|
R
|
Range Resources Corp
DUS:RAX
|
US |
|
RH
LSE:0KTF
|
US |
|
R
|
Ryanair Holdings PLC
LSE:0RYA
|
IE |
|
Avenue Supermarts Ltd
NSE:DMART
|
IN |
|
Dr Martens PLC
LSE:DOCS
|
UK |
|
L
|
Lipocine Inc
F:2VT
|
US |
Wall St Price Targets
NG9 Price Targets Summary
Neogenomics Inc
Neogenomics Inc
Wall Street analysts forecast NG9 stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for NG9 is 11.91 EUR with a low forecast of 5.92 EUR and a high forecast of 14.95 EUR.
Lowest Forecast
Price Target
5.92
EUR
23% Downside
Average Forecast
Price Target
11.91
EUR
55% Upside
Highest Forecast
Price Target
14.95
EUR
95% Upside
Neogenomics Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NG9's stock price target?
Price Target
11.91
EUR
11.91
EUR
According to Wall Street analysts, the average 1-year price target for NG9 is 11.91 EUR with a low forecast of 5.92 EUR and a high forecast of 14.95 EUR.
What is the Revenue forecast for Neogenomics Inc?
Projected CAGR
9%
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 21%. The projected CAGR for the next 5 years is 9%.
